'Devastating' Trump Cuts to FDA, NIH Will Result in Fewer Medications, New Analysis Warns

One former federal health official said Friday that medications with the potential to "substantially change healthcare and improve the lives of patients" are likely to be among the dozens that won't be developed if Republicans pass a proposal by the Trump administration to slash crucial health research funding.

Jeremy Berg, a former director of the National Institute of General Medical Sciences at the National Institutes of Health, was referring to an analysis by the Congressional Budget Office (CBO) of President Donald Trump's proposal to cut funding to the NIH by 40%—budget cuts that experts have warned would kneecap the country's ability to research emerging health threats and treatments, while terminating the United States' position as a world leader in medical innovation.

"The lost drugs" resulting from the budget cuts, Berg told The New York Times, "are more likely to be the novel 'first in class' drugs."

The CBO found that even a 10% reduction in the NIH budget would stop an estimated 30 new medications from coming to market over the next three decades.

A reduction in the agency's external preclinical research "would ultimately decrease the number of new drugs coming to market by roughly 4.5%, or about two drugs per year," the CBO said, with the impact of the budget cuts growing over three decades.

The CBO also analyzed proposals that would affect the Food and Drug Administration (FDA), including one that would cut staff and result in increased review times for new medications by nine months. By the second decade of the policy being in effect, said the CBO, 10 fewer drugs would be approved each decade—a 2% reduction—with 23 new medications ultimately being prevented from coming to market.

Already, the FDA's workforce has been reduced by about 15%, with 3,500 people losing their jobs or resigning.

The Times reported that the FDA has approved 25 new drugs so far in 2025; it has authorized an average of 60 new medications per year in the past.

"This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."

A group of Democratic lawmakers who serve as ranking members of key committees emphasized that the CBO's analysis likely vastly underestimates the impact Trump's proposed cuts would have on the NIH, as it investigated the potential impact of just a 10% budget cut rather than the full 40% cut the president has proposed.

"The proposed cuts are so enormous that CBO's own model is unable to produce an estimate," said U.S. Reps. Brendan Boyle (D-Pa.), ranking member of the House Budget Committee, and Frank Pallone (D-N.J.), along with Sens. Bernie Sanders (I-Vt.) and Jeff Merkley (D-Ore.).

"The United States leads the world in medical innovation because of our continued investments in research and development at the NIH," said the lawmakers. "Every $1 invested in NIH research returns $2.50 to the U.S. economy. This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."

"The United States' effort to bring cutting-edge treatments to patients with cancers, rare diseases, cardiovascular diseases, and neurodegenerative diseases," they added, "will come to a grinding halt because of the Trump administration's devastating cuts to NIH and FDA funding."